Neuroprotection in the complex treatment of primary glaucoma

Abstract

Neuroprotection is a direction in therapy that prevents the loss of neurons due to external factors. In glaucoma, the use of both direct and indirect neuroprotection is pathogenetically justified, which, respectively, can have a direct protective effect on retinal ganglion cells, or affect various risk factors for the development of neuropathy. At present, Retinalamin — a complex of peptides isolated from cattle retinas — is used in ophthalmology for neuroprotective purposes. Although the clinical efficacy and safety of Retinalamin is well established, its exact mechanism of action remains unclear. To amend this, in vitro studies of its cytotoxicity and efficacy were carried out, as well as a comparison of its effectiveness in various ways of administration, and a retrospective analysis of its use.